A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Overview
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Source
Originally published at www.cnbc.com.
Related Articles
- ‘Day-to-day dread’ haunts frustrated job seekers in era of low hiring. When will it end?
- Fed Governor Christopher Waller Just Drove a Dagger Through President Donald Trump's Demand for Lower Interest Rates
- Should Investors Be Concerned That Walmart Got Kicked Out of the $1 Trillion Club and Now the $900 Billion Club?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.